Brief: Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint
10/06/2026 16:33
BRIEF-Alphamab Oncology Says Phase III Clinical Study Of Anbenitamab Met Primary Endpoint June 10 (Reuters) - Alphamab Oncology 9966.HK:
PHASE III CLINICAL STUDY OF ANBENITAMAB (KN026) AS FIRST-LINE TREATMENT FOR HER2+ ADVANCED BREAST CANCER MET PRIMARY ENDPOINT
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines